Patents by Inventor Guolong DU

Guolong DU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240336594
    Abstract: A compound of formula I and a use thereof as an MALT1 inhibitor, and a pharmaceutical composition containing the compound. The compound can be used to treat diseases or disorders such as cancer.
    Type: Application
    Filed: June 24, 2022
    Publication date: October 10, 2024
    Inventors: Bang FU, Yinlong LI, Wei REN, Qichao SHEN, Guolong DU, Xiaojun ZHOU, Yun SUN, Yuzhen ZHOU, Xiao SUN, Weidong CAI, Xiangyong LIU, Lieming DING, Jiabing WANG
  • Publication number: 20230133169
    Abstract: Provided are the compounds of Formula I, a method for using these compounds as an EGFR inhibitor, and a pharmaceutical composition comprising the compounds. The compound is used for treatment, prevention or amelioration of diseases or conditions such as cancer or infection.
    Type: Application
    Filed: October 13, 2020
    Publication date: May 4, 2023
    Applicant: BETTA PHARMACEUTICALS CO., LTD
    Inventors: Xiangyong LIU, Changyong QIU, Guolong DU, Qichao SHEN, Mengqiang LIU, Haitong SHENG, Lieming DING, Jiabing WANG
  • Publication number: 20230131025
    Abstract: The present invention relates to a compound of formula (I), a method for using the compound as an EGFR inhibitor, and a pharmaceutical composition comprising the compound. The compound can be used for treatment, prevention or alleviation of diseases or disorders such as cancer or infection.
    Type: Application
    Filed: February 8, 2021
    Publication date: April 27, 2023
    Applicant: Betta Pharmaceuticals Co., Ltd.
    Inventors: Xiangyong LIU, Changyong QIU, Mengqiang LIU, Xiaodong SONG, Qichao SHEN, Guolong DU, Haitong SHENG, Lieming DING, Jiabing WANG
  • Publication number: 20220402948
    Abstract: The present invention relates to the compounds of Formula I, methods of using these compounds as EGFR inhibitors, and pharmaceutical compositions comprising compounds thereof. The compounds are used for treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: September 25, 2020
    Publication date: December 22, 2022
    Inventors: Xiangyong LIU, Changyong QIU, Haitong SHENG, Mengqiang LIU, Qichao SHEN, Guolong DU, Xiaodong SONG, Lieming DING, Jiabing WANG
  • Publication number: 20220259235
    Abstract: The present invention relates to compounds of Formula I, methods of using the compounds as EGFR inhibitors, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: July 23, 2020
    Publication date: August 18, 2022
    Inventors: Xiangyong Liu, Changyong Qiu, Qichao Shen, Mengqiang Liu, Haitong Sheng, Xiaodong Song, Guolong Du, Jiabing Wang, Lieming Ding
  • Publication number: 20220227796
    Abstract: The present invention relates to compounds of Formula I, methods of using the compounds as EGFR inhibitors, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: March 31, 2020
    Publication date: July 21, 2022
    Inventors: Xiangyong LIU, Changyong QIU, Qichao SHEN, Mengqiang LIU, Haitong SHENG, Guolong DU, Jiabing WANG, Lieming DING